Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers

This study has been terminated.
(recruitment difficulties)
Sponsor:
Information provided by (Responsible Party):
Erchonia Corporation
ClinicalTrials.gov Identifier:
NCT01376050
First received: June 16, 2011
Last updated: April 7, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to determine whether low level laser light therapy is effective as an adjunctive therapy to the healing of venous stasis leg ulcers.


Condition Intervention
Venous Stasis Ulcer
Device: Erchonia ML Scanner (MLS)
Device: Inactive Erchonia ML Scanner (MLS)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers

Resource links provided by NLM:


Further study details as provided by Erchonia Corporation:

Primary Outcome Measures:
  • The number of venous stasis ulcers that achieve complete wound closure within the 12-week treatment period. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
    'Complete wound closure' is defined as skin re-epithelialization without drainage or dressing requirements confirmed across a consecutive two-week evaluation period. Incidence of complete wound closure will be evaluated for venous stasis ulcers in the test versus placebo subject groups. Efficacy success is defined as a statistically significant greater proportion of venous stasis ulcers in the test procedure group achieving complete wound closure compared with the proportion of venous stasis ulcers in the placebo procedure group achieving complete wound closure.


Secondary Outcome Measures:
  • Time to complete wound closure for venous stasis ulcers. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
    'Complete wound closure' is defined as skin re-epithelialization without drainage or dressing requirements confirmed across a consecutive two-week evaluation period. Time to complete wound closure will be evaluated for venous stasis ulcers in the test versus placebo subject groups.


Enrollment: 13
Study Start Date: June 2011
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Inactive Erchonia ML Scanner (MLS)
Non-therapeutic output simulating that of the active laser but providing no therapeutic benefit.
Device: Inactive Erchonia ML Scanner (MLS)
no therapeutic output emitted.
Active Comparator: Erchonia ML Scanner (MLS)
Active low level light laser device comprising three 17.5 milliWatts (mW) 635 nanometer (nm) diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
Device: Erchonia ML Scanner (MLS)
Active low level light laser device comprising three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.

Detailed Description:

A chronic venous stasis leg ulcer is a wound below the knee that fails to heal within 6 weeks. Venous stasis ulcers account for 80% to 90% of all leg and foot ulcers, affecting an estimated 500,000-600,000 people in the United States every year. Venous stasis ulcers account for the loss of 2 million working days and incur treatment costs around $3 billion dollars annually in the United States. Standard of care for venous stasis ulcers includes compression of the affected leg together with daily dressing changes to minimize swelling; debridement of the ulcer to remove dead tissue and bacteria; and daily wound Care dressing to keep the wound clean. Venous stasis ulcers typically have very lengthy and poor healing rates, with up to 50% remaining open and unhealed for 9 months or longer. Many patients suffer pain and sleep and mobility problems, impairing quality of life. Recurrence rates for venous stasis ulcers is very high, with about one third of treated individuals experiencing 4 or more episodes of ulceration.

Low level laser light therapy (LLLT), with its proven tissue healing acceleration properties has recently gained attention as a simple, non-invasive alternative adjunctive therapy to assist in both wound closure and accelerated time to wound closure. Numerous histological trials have exhibited laser therapy's capacity to upregulate essential wound-healing factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), oxygen concentration, PI3 kinase/eNOS, fibroblast proliferation, collagen synthesis, re-epithelialization, and tissue granulation. Clinically, the application of laser therapy has demonstrated promise, accelerating the rate of wound healing and tissue contracture.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least one venous stasis ulcer, diagnosed according to a differential diagnosis methodology that satisfies both criteria supportive of the ulcer's venous origin and criteria that eliminates the ulcer as being indicative of non-venous origin. Diagnostic criteria to evaluate satisfaction of criteria that is supportive of venous origin of the ulcer will involve an evaluation of medical history and wound history variables; physical examination of the affected leg and ulcer site; and objective testing
  • Resting Ankle Brachial Pressure Index (ABPI) of 0.8 or greater
  • Venous Doppler ultrasound shows reflux in the suspect vein
  • CEAP Class 6
  • Ulcer measures 5 to 20cm², inclusive, according to standardized computerized planimetry evaluation
  • presenting venous leg ulcer has been present for 6 continuous weeks or longer
  • Subject agrees to not partake in any other form of treatment for the ulcer throughout study participation, other than the standard of care treatment provided by the investigator as part of the study protocol

Exclusion Criteria:

  • Satisfaction of any exclusive diagnostic criteria that is considered indicative of an ulcer being of non-venous origin (e.g. arterial or mixed origin), or as having a non-venous component. This evaluation will include consideration of medical history and wound history variables; examination of the affected leg and ulcer site; and objective tests and measurements
  • Resting Ankle Brachial Pressure Index (ABPI) of less than 0.8
  • Doppler ultrasound that shows absence of reflux in the suspect vein
  • Fasting blood glucose (blood sugar) level of greater than 140 mg/dl that is indicative of current or potential diabetes
  • Subject presents with factors that may significantly impede or delay the healing of chronic non-healing wounds, including known diabetes or other disordered glucose metabolic disease; malnutrition; collagen diseases such as Ehlers-Danlos syndrome; history of systematic glucocorticosteroid therapy; history of exogenous glucocorticosteroid therapy; and chemotherapeutic (antineoplastic) drug use
  • Ulcer has significant bacterial infection, confirmed by a positive swab culture utilizing Levine's technique
  • Ulcer has been present for less than 6 continuous weeks
  • Ulcer is of CEAP Class 0 through 5, inclusive
  • Ulcer measures less than 5cm² or greater than 20cm², according to standardized computerized planimetry evaluation
  • Exposed bone tendon or fascia
  • General skin disorder such as psoriasis or penicilitis
  • Immunosuppressive disorder
  • Hypercoagulable state
  • Prior deep vein thrombosis
  • Cellulites during the one-year period prior to study participation in
  • Vasculitis or collagen vascular disease
  • History of prior venous surgery
  • Any concomitant illness(es) or medical condition(s) that would render the subject inappropriate for the study (i.e., renal failure, liver disease, connective tissue disorders, etc.)
  • Active or recurrent cancer or currently receiving chemotherapy or radiation therapy
  • Subject is taking a regimen of any medication(s) that may affect wound healing, including corticosteroid, chemotherapeutic and non-steroidal anti-inflammatory (NSAID) medications
  • Developmental disability/significant psychological disorder that could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years
  • Females currently pregnant or lactating or intending to attempt to become pregnant during the course of intended study participation
  • Involvement in litigation/receiving disability benefits related to venous stasis ulcer(s).
  • Other research participation in the 30 days prior to study qualification evaluation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01376050

Locations
United States, Texas
Jeffrey Kenkel, MD
Dallas, Texas, United States, 75390
France
Luc Teot, MD
Montpellier, France
Sponsors and Collaborators
Erchonia Corporation
Investigators
Principal Investigator: Jeffery Kenkel, MD
  More Information

No publications provided

Responsible Party: Erchonia Corporation
ClinicalTrials.gov Identifier: NCT01376050     History of Changes
Other Study ID Numbers: EC_VSU
Study First Received: June 16, 2011
Last Updated: April 7, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Erchonia Corporation:
venous stasis ulcer
leg ulcer

Additional relevant MeSH terms:
Postphlebitic Syndrome
Postthrombotic Syndrome
Ulcer
Varicose Ulcer
Cardiovascular Diseases
Embolism and Thrombosis
Leg Ulcer
Pathologic Processes
Peripheral Vascular Diseases
Phlebitis
Skin Diseases
Skin Ulcer
Thrombosis
Varicose Veins
Vascular Diseases
Venous Insufficiency
Venous Thrombosis

ClinicalTrials.gov processed this record on November 20, 2014